Mint Hits 43% on JUUL Relaunch Market Despite No FDA Authorization for Mint

---

JUUL's Mint Flavor Just Surged 15 Points on Prediction Markets. Here's the Tension Behind That Move

JUUL stopped selling mint-flavored pods in November 2019, citing published research showing their popularity among young people. Nearly seven years later, mint has never returned to American retail. The FDA has never issued a marketing authorization for it. No public filing, no leaked memo, no executive statement in the last 72 hours confirms that a relaunch is imminent.

Yet prediction markets just repriced mint as if one were. On the question of what flavors JUUL will relaunch by end of 2026, mint's implied probability climbed from 28% to 43% over three days, a 15-percentage-point surge that represents the sharpest move on this contract in recent weeks. From the period low of 20%, the swing is even more dramatic: 23 points of upward repricing with no confirmed catalyst to explain it.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Mint

Consensus YES price across 1 venues

52%average

PolymarketBest YES price98¢

I could not identify a specific news event, regulatory filing, or corporate announcement within the last 72 hours that explains this move. The surge may reflect speculative positioning, trader coordination, or private information that hasn't surfaced publicly. What I can do is explain why the market is interested in mint at all, and why traders should treat this price with serious caution.

---

Mint Was JUUL's Crown Jewel: The Flavor That Built an Empire and Triggered a Crisis

Mint wasn't just one of JUUL's flavors. It was the flavor. After JUUL discontinued mango, crème, fruit, and cucumber pods in late 2018, mint absorbed much of the displaced demand and became the company's single best-selling SKU. Research published in JAMA in late 2019 found that mint was the most popular JUUL flavor among U.S. 10th- and 12th-grade users.

JUUL pulled mint voluntarily, not under FDA order. The distinction matters. The company cited published research on youth use when announcing the withdrawal. That means no regulatory prohibition specifically bars mint's return. The barrier is the absence of an approval, not the presence of a ban.

The commercial logic for bringing mint back is uncomplicated. JUUL's U.S. product line has been limited to tobacco and menthol since late 2019. In a market where competitors like Vuse and NJOY have gained share, restoring JUUL's most popular flavor would be the single most effective revenue lever the company could pull. This is presumably what bettors are pricing: the economic incentive is so strong that JUUL will eventually find a regulatory path.

---

What the FDA Has Actually Said About JUUL Mint, and Why Silence Isn't Approval

On July 17, 2025, the FDA authorized the JUUL device and Virginia Tobacco and Menthol JUULpods in two nicotine strengths. Those five authorized products did not include mint. The authorization therefore does not establish a regulatory path for a mint relaunch.

The broader Premarket Tobacco Product Application process has been severe for flavored e-cigarettes. The FDA has denied millions of flavored vape applications since 2021, consistently citing insufficient evidence that the products' benefit to adult smokers outweighs the risk of youth initiation. Mint occupies the worst possible position in this framework. It is the flavor most directly associated with the youth vaping epidemic that prompted the entire regulatory crackdown.

JUUL has submitted comments to the FDA on flavored e-cigarette guidance and released a position paper in December 2023 advocating for a menthol tobacco product standard. These filings suggest the company is building a regulatory argument around menthol specifically, not mint. The distinction between menthol (positioned as an adult switching tool) and mint (associated with youth appeal) is one the FDA has drawn repeatedly. JUUL's own public strategy appears to respect that line.

---

The Strongest Case Against Mint: History, Politics, and the FDA's Track Record

Here is the genuine bear case, and it deserves full weight. Mint is not merely a flavor the FDA hasn't approved. It is the flavor whose youth popularity catalyzed the entire modern vaping regulatory apparatus. Authorizing JUUL mint would be the most politically charged decision the FDA's Center for Tobacco Products could make, potentially reopening the same Congressional and public health scrutiny that nearly destroyed JUUL in 2019 and 2020.

The FDA's institutional incentives run strongly against approval. No FDA commissioner wants to authorize the exact product that fueled the youth vaping crisis. Even if JUUL could demonstrate through rigorous clinical data that mint helps adult smokers switch from combustible cigarettes, the political cost is one the agency has every reason to avoid. The asymmetry is stark: the downside of approving mint (youth vaping headlines, Congressional hearings) is far more visible than the upside (marginally better cessation outcomes among adults who prefer mint over menthol).

There is also a timing problem. This market resolves on December 31, 2026. The FDA authorized the original JUUL device and specified tobacco and menthol pods in July 2025. That authorization does not establish whether or when a mint product could be authorized.

---

What 43% Actually Means for This Market

At 43%, the market is saying there's roughly a two-in-five chance that JUUL relaunches mint by December 31, 2026. That pricing requires you to believe either that JUUL has already secured or is close to securing FDA clearance for mint, or that the company will relaunch without explicit authorization and manage the legal consequences.

Neither scenario is impossible. But neither has any public evidence supporting it. The 15-point surge appears to be sentiment-driven rather than information-driven, which makes it fragile. Sentiment-driven moves without a confirmed catalyst tend to revert unless subsequent news validates them.

Traders should watch for two concrete signals: any PMTA filing or amendment specifically covering mint (which would be disclosed in FDA databases) and any change in JUUL's public regulatory strategy that moves beyond menthol advocacy toward a broader flavored products argument. Until one of those appears, 43% prices in more optimism than the regulatory record can support.